Patients with MetS are characterized by chronic systemic inflammation, a process related to oxidative stress and genetic mutations; several studies have shown a close correlation between the progression of the dysmetabolic process and an altered increase in the release of adipokines including tumor necrosis factor alpha (TNF a) and interleukin-6 (IL-6) linked with a progressive activation of the innate immune system [14,15,16]. Here, IL6 is linked to metabolic syndrome.